SIGA
SIGA Technologies, Inc. NASDAQ Listed Sep 10, 1997$4.32
+0.23%
vs $4.31
Mkt Cap $309.8M
52w Low $4.10
4.0% of range
52w High $9.62
50d MA $4.50
200d MA $6.31
P/E (TTM)
13.1x
EV/EBITDA
6.4x
P/B
1.6x
Debt/Equity
0.0x
ROE
11.7%
P/FCF
6.3x
RSI (14)
30.40
ATR (14)
$0.11
Beta
1.06
50d MA
$4.50
200d MA
$6.31
Avg Volume
494.6K
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.
31 East 62nd Street · New York City, NY 10065 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | — | -0.05 | — | 4.73 | -1.9% | +1.5% | -5.2% | -2.2% | -3.1% | -1.2% | — |
| Mar 10, 2026 | AMC | — | -0.08 | — | 5.65 | +0.0% | -3.0% | -0.2% | -3.8% | +3.8% | -8.1% | — |
| Nov 6, 2025 | AMC | — | -0.09 | — | 8.17 | -10.6% | -20.0% | -0.5% | -3.4% | -1.3% | -2.1% | — |
| Aug 5, 2025 | AMC | — | 0.49 | — | 6.60 | +5.9% | +10.0% | +17.8% | +4.8% | +5.8% | -1.9% | — |
| May 8, 2025 | AMC | — | -0.01 | — | 5.44 | -0.7% | +4.0% | +4.9% | +0.0% | -0.2% | -0.2% | — |
| Mar 11, 2025 | AMC | — | 0.63 | — | 5.60 | +4.5% | +7.0% | -9.0% | +2.4% | +0.9% | +2.3% | — |
| Nov 7, 2024 | AMC | — | 0.02 | — | 7.63 | -0.1% | -0.8% | -0.4% | -6.4% | -6.4% | -4.7% | — |
| Aug 1, 2024 | AMC | — | 0.03 | — | 9.24 | -6.7% | -5.8% | -5.4% | +3.9% | +1.8% | +5.5% | — |
| May 7, 2024 | AMC | — | 0.14 | — | 10.46 | -1.9% | -28.3% | +3.3% | -3.7% | -0.1% | +5.4% | — |
| Mar 12, 2024 | AMC | — | 1.01 | — | 5.32 | +12.6% | +21.2% | +7.1% | +6.1% | +8.5% | +4.9% | — |
| Nov 7, 2023 | AMC | — | -0.01 | — | 5.16 | -11.2% | -6.6% | +2.1% | +0.2% | -0.8% | +1.0% | — |
| Aug 8, 2023 | AMC | — | -0.04 | — | 5.77 | -5.9% | -6.2% | -3.0% | -3.6% | -1.4% | +1.6% | — |
| May 4, 2023 | AMC | — | -0.01 | — | 5.82 | +3.3% | +1.9% | -3.7% | +0.5% | +1.6% | +6.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 6 | Wedbush | Maintains | Outperform → Outperform | — | $2.91 | $2.93 | +0.7% | +1.4% | -2.4% | -5.9% | -1.5% | +0.0% |
No insider trades available.
8-K · 5.02
!!! Very High
SIGA Technologies, Inc. -- 8-K 5.02: Executive Change
Jun 10
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
SIGA filed an 8-K with minimal disclosed details, suggesting either a routine filing or withheld material information; investors should seek clarification on the actual announcement to assess relevance.
Mar 26
8-K
Unknown — 8-K Filing
SIGA's $88M TPOXX revenue in 2025 plus a $13M international order signal strong demand for its monkeypox treatment, suggesting sustained revenue growth and improved earnings visibility for the biotech stock.
Mar 10
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Altravue Capital, Llc | 2,432,024 | $13M | Added | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 1,714,380 | $9M | New | Mar 2026 |
| 3 | Arrowstreet Capital, Limited Partnership | 1,525,960 | $8M | Added | Mar 2026 |
| 4 | Aqr Capital Management Llc | 1,219,677 | $7M | Added | Mar 2026 |
| 5 | Morgan Stanley | 988,912 | $6M | Reduced | Dec 2025 |
| 6 | First Wilshire Securities Management Inc | 890,498 | $5M | Added | Mar 2026 |
| 7 | Citadel Advisors Llc | 705,137 | $4M | Reduced | Mar 2026 |
| 8 | Vanguard Portfolio Management Llc | 586,974 | $3M | New | Mar 2026 |
| 9 | Legato Capital Management Llc | 512,039 | $3M | Reduced | Mar 2026 |
| 10 | Bank Of America Corp /de/ | 484,672 | $3M | Reduced | Mar 2026 |
| 11 | Renaissance Technologies Llc | 475,013 | $3M | Added | Mar 2026 |
| 12 | Millennium Management | 466,324 | $2M | Reduced | Mar 2026 |
| 13 | D.e. Shaw & Co | 456,385 | $2M | Reduced | Mar 2026 |
| 14 | Two Sigma Investments, Lp | 433,661 | $2M | Added | Mar 2026 |
| 15 | Qube Research & Technologies Ltd | 415,104 | $2M | Added | Mar 2026 |
| 16 | Victory Capital Management Inc | 376,571 | $2M | Added | Mar 2026 |
| 17 | Uniplan Investment Counsel, Inc. | 371,413 | $2M | Reduced | Mar 2026 |
| 18 | Hrt Financial Lp | 360,067 | $2M | New | Mar 2026 |
| 19 | Northern Trust Corp | 340,175 | $2M | Reduced | Mar 2026 |
| 20 | Segall Bryant & Hamill, Llc | 273,522 | $1M | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$309.8M
Enterprise Value
$154.4M
P/E (TTM)
13.09x
Forward P/E
2.54x
PEG Ratio
-0.31x
P/B
1.56x
P/S
3.27x
P/FCF
6.35x
EV/EBITDA
6.36x
Shares Out
71.6M
Financials (TTM)
Revenue
$94.6M
Net Income
$23.3M
EBITDA
$24.3M
Free Cash Flow
$48.7M
Op Cash Flow
$48.8M
EPS Basic
$0.33
EPS Diluted
$0.33
EPS Forward
$1.70
Gross Margin
68.6%
Op Margin
25.1%
Net Margin
24.6%
Balance Sheet
Total Assets
$219.5M
Total Liab.
$20.6M
Total Equity
$198.8M
Cash
$155.0M
LT Debt
$0
Book Value/Sh
$2.78
Debt/Equity
0.00x
Current Ratio
11.83
Quick Ratio
9.10
Returns & Growth
ROE
11.7%
ROA
10.6%
ROIC
9.0%
Rev Growth YoY
-31.8%
EPS Growth YoY
-60.2%
Price Returns
2W
+9.9%
1M
+1.7%
3M
-27.7%
6M
-22.8%
12M
-21.7%
Technicals
52W High
$9.62
52W Low
$4.10
50d MA
$4.50
200d MA
$6.31
RSI (14)
30.40
ATR (14)
$0.11
Beta
1.06
Avg Volume
495K
Dividends
Div Rate
$0.60
Div Yield
13.1%
Frequency
—
Ex-Div Date
Apr 7, 2026
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 27, 2026 1:16am
· Source: financialmodelingprep.com